fda semaglutide compounding warning november 2025 Compounded "semaglutide" is not FDA-approved The FDA has issued warning

The article states that the IRS does not automatically approve weight-loss medications, and that eligibility rests on the medication being prescribed to treat a diagnosed condition, including obesity when medically indicated

The anti-inflammatory properties of omega 3s, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), help protect hair follicles from inflammatory damage that can disrupt the natural hair growth cycle

Direct-to-consumer platforms that are powered by telehealth, digital marketing, and cash-pay models are reshaping access to prescription drugs

Long-term use at very high doses and interactions with certain medications (particularly nitroglycerin and potentially anticoagulants) warrant provider guidance